PMID- 34003510
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20240226
IS  - 1098-2744 (Electronic)
IS  - 0899-1987 (Linking)
VI  - 60
IP  - 7
DP  - 2021 Jul
TI  - The LncRNA FGD5-AS1/miR-497-5p axis regulates septin 2 (SEPT2) to accelerate 
      cancer progression and increase cisplatin-resistance in laryngeal squamous cell 
      carcinoma.
PG  - 469-480
LID - 10.1002/mc.23305 [doi]
AB  - Aberrant expression or mutation of the Septin gene family is closely associated 
      with cancer progression, and septin 2 (SEPT2) exerts its tumor-promoting effects 
      in multiple cancers, but its role in regulating laryngeal squamous cell carcinoma 
      (LSCC) progression and drug resistance has not been investigated. Based on the 
      published data, the present study identified that SEPT2 promoted cancer 
      progression and increased cisplatin-resistance in LSCC, and a novel LncRNA 
      FGD5-AS1/miR-497-5p axis was crucial for this process. Mechanistically, SEPT2 
      tended to be enriched in LSCC tissues and cells, and knock-down of SEPT2 
      inhibited cell proliferation, viability, migration, and tumorigenesis in LSCC 
      cells in vitro and in vivo. Aside from that, SEPT2 overexpression increased 
      cisplatin resistance in LSCC cells. Next, by conducting the dual-luciferase 
      reporter gene system assay, we identified that the LncRNA FGD5-AS1/miR-497-5p 
      axis regulated SEPT2 in LSCC. Specifically, LncRNA FGD5-AS1 sponged miR-497-5p to 
      upregulate SEPT2 in LSCC cells in a competing endogenous RNA (ceRNA) 
      mechanisms-dependent manner. Interestingly, upregulated LncRNA FGD5-AS1 and 
      downregulated miR-497-5p were observed in LSCC tissues and cells, and LncRNA 
      FGD5-AS1 ablation inhibited cancer progression. Also, LncRNA FGD5-AS1 
      overexpression increased cisplatin-resistance in LSCC by modulating the 
      miR-497-5p/SEPT2 axis. Collectively, we conclude that targeting the LncRNA 
      FGD5-AS1/miR-497-5p/SEPT2 signaling cascade may be an alternative strategy to 
      treat LSCC in the clinic.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Song, Kaibin
AU  - Song K
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, Heilongjiang, China.
FAU - Yu, Pingyang
AU  - Yu P
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, Heilongjiang, China.
FAU - Zhang, Cong
AU  - Zhang C
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, Heilongjiang, China.
FAU - Yuan, Zhennan
AU  - Yuan Z
AUID- ORCID: 0000-0001-5832-6562
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, Heilongjiang, China.
FAU - Zhang, Hailin
AU  - Zhang H
AD  - Department of Head and Neck Surgery, Hunan Cancer Hospital, Changsha, Hunan, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210518
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
RN  - 0 (3' Untranslated Regions)
RN  - 0 (MIRN497 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 3.6.1.- (SEPTIN2 protein, human)
RN  - EC 3.6.1.- (Septins)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cisplatin/pharmacology
MH  - Drug Resistance, Neoplasm/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Head and Neck Neoplasms/drug therapy/genetics/*pathology
MH  - Humans
MH  - Mice, Inbred BALB C
MH  - MicroRNAs/*genetics
MH  - RNA, Long Noncoding/*genetics
MH  - Septins/*genetics/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/drug therapy/genetics/*pathology
MH  - Xenograft Model Antitumor Assays
MH  - Mice
OTO - NOTNLM
OT  - LncRNA FGD5-AS1
OT  - cancer biology
OT  - laryngeal carcinoma
OT  - miR-497-5p
OT  - septin 2
EDAT- 2021/05/19 06:00
MHDA- 2021/08/20 06:00
CRDT- 2021/05/18 12:27
PHST- 2021/04/14 00:00 [revised]
PHST- 2020/12/18 00:00 [received]
PHST- 2021/04/21 00:00 [accepted]
PHST- 2021/05/19 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2021/05/18 12:27 [entrez]
AID - 10.1002/mc.23305 [doi]
PST - ppublish
SO  - Mol Carcinog. 2021 Jul;60(7):469-480. doi: 10.1002/mc.23305. Epub 2021 May 18.